Program
velzatinib
Also written as “Velzatinib” and “IDRX-42”.
In GlaxoSmithKline's pipeline, KIT inhibitor
. Its studies are mostly in Gastrointestinal Stromal Tumors · Gastrointestinal Neoplasms, led by GlaxoSmithKline.
Furthest: phase 3, since Oct 17, 20258 company-led studies, 8 open or runningNext primary completion: Jan 12, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 88 open or running | phase 3since Oct 17, 2025 | Jul 28, 2022 | Jan 12, 2027phase 1 · NCT07862114 |
- Named in GlaxoSmithKline’s own pipeline as
velzatinib GSK6042981
, phase 3, as of Sep 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 28, 2022First study: phase 1 study in Gastrointestinal NeoplasmsFirst studyNCT05489237 · 276 enrolled · United States, Belgium, China and more
- Oct 17, 2025Phase 3 study in Gastrointestinal NeoplasmsNCT07218926 · 450 planned · United States, Australia, Belgium and more
- May 6, 2026Phase 3 study in Gastrointestinal Stromal TumorsNCT07585266 · 800 planned · United States, Argentina, Australia and more
- Jul 1, 2026Phase 2 study in Gastrointestinal NeoplasmsNCT07689201 · 24 planned · Japan
- Sep 22, 2026Phase 2 study in Gastrointestinal NeoplasmsNCT07843641 · 72 planned
- Oct 1, 20263 phase 1 studies in Gastrointestinal NeoplasmsNCT07867171, NCT07862114, NCT07859735
Ahead
- Jan 12, 2027Primary completion: phase 1 study in Gastrointestinal NeoplasmsNCT07862114
- Mar 10, 2027Primary completion: phase 1 study in Gastrointestinal NeoplasmsNCT05489237
- Sep 9, 2027Primary completion: phase 1 study in Gastrointestinal NeoplasmsNCT07867171
- Nov 29, 2027Primary completion: phase 2 study in Gastrointestinal NeoplasmsNCT07689201
TargetBeta
“KIT inhibitor”the company's pipeline, read by Claude · source
“An orally bioavailable small molecule inhibitor of multiple mutated forms of mast/stem cell factor receptor KIT (c-Kit; SCFR), ”NCIt, by rule
Other programs on KIT
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| imatinibrule | Novartis | phase 4 | 70 |
| regorafenibrule | Bayer | phase 4 | 40 |
| Avapritinibrule | Sanofi | phase 4 | 10 |
| anlotinibrule | Sino Biopharmaceutical | phase 3 | 40 |
| masitinibrule | AB Science | phase 3 | 38 |
| quizartinibrule | Daiichi Sankyo | phase 3 | 22 |
| ripretinibrule | Ono Pharmaceutical | phase 3 | 9 |
| seralutinibrule | gb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-inc | phase 3 | 8 |
| elenestinib | Sanofi | phase 3 | 3 |
| NB-003rule | ningbo-newbay-technology-development-co-ltd | phase 3 | 2 |
| briquilimabrule | jasper-therapeutics-inc | phase 2 | 7 |
| BLU-808 | Sanofi | phase 2 | 3 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07867171Gastrointestinal Neoplasms | 1 | Not yet recruiting | Sep 9, 2027 | 30 |
| NCT07862114Gastrointestinal Neoplasms | 1 | Not yet recruiting | Jan 12, 2027 | 36 |
| NCT07859735Gastrointestinal Neoplasms | 1 | Not yet recruiting | Apr 25, 2028 | 40 |
| NCT07843641Gastrointestinal Neoplasms | 2 | Not yet recruiting | Jan 31, 2031 | 72 |
| NCT07689201Gastrointestinal Neoplasms · Japan | 2 | Recruiting | Nov 29, 2027 | 24 |
| NCT07585266Gastrointestinal Stromal Tumors · United States, Argentina, Australia and more | 3 | Recruiting | Aug 30, 2032 | 800 |
| NCT07218926Gastrointestinal Neoplasms · United States, Australia, Belgium and more | 3 | Recruiting | May 30, 2028 | 450 |
| NCT05489237Gastrointestinal Neoplasms · United States, Belgium, China and more | 1 | Active, not recruiting | Mar 10, 2027 | 276 |
How it is read
Names in the registry
- “Velzatinib”, 6 entries
- “IDRX-42”, 2 entries
Conditions, from the studies’ own filings
- Gastrointestinal Stromal Tumors, 5 studies
- Gastrointestinal Neoplasms, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.